{"created":"2023-05-15T16:41:39.451224+00:00","id":16360,"links":{},"metadata":{"_buckets":{"deposit":"f2b1d0e9-fbb0-4d7e-bc99-458dded05983"},"_deposit":{"created_by":2,"id":"16360","owners":[2],"pid":{"revision_id":0,"type":"depid","value":"16360"},"status":"published"},"_oai":{"id":"oai:nagasaki-u.repo.nii.ac.jp:00016360","sets":["8:9"]},"author_link":["61892","61893","61891"],"item_2_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2009-02","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"2","bibliographicPageEnd":"311","bibliographicPageStart":"303","bibliographicVolumeNumber":"135","bibliographic_titles":[{"bibliographic_title":"Journal of cancer research and clinical oncology"}]}]},"item_2_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"PURPOSE: Inhibition of phosphoinositide 3 (PI3)-kinase pathway is attractive for cancer treatment. To examine the role of the phosphatase and tensin homolog (PTEN) in the development of resistance to the treatment. METHODS: We cultured human prostate cancer cells (DU145 and PC-3 cells) and bladder cancer cells (EJ-1 and UM-UC-3 cells) with a PI3-kinase inhibitor, LY294002 for more than 6 weeks and cell proliferation was studied. Activation of Akt1 and ERK was examined by immunoblotting. We introduced the wild type PTEN in UM-UC-3 cells and their proliferation along with the signaling pathways was also examined. RESULTS: After 6 weeks, proliferation pathway sensitivity to LY294002 was reduced in cells expressing PTEN, but not in PTEN-null cells. PD98059, a MAPK/ERK kinase inhibitor, significantly inhibited proliferation of PTEN-expressing cells, but not PTEN-null cells. Stable PTEN expression in PTEN-null UM-UC-3 cells increased serum-induced ERK activation and sensitivity to PD98059-treatment, and reduced sensitivity to LY294002 after 6 weeks of exposure. CONCLUSIONS: Loss of PTEN function may protect against resistance to PI3-kinase inhibitors through an addiction to the PI3-kinase/Akt pathway.","subitem_description_type":"Abstract"}]},"item_2_description_63":{"attribute_name":"引用","attribute_value_mlt":[{"subitem_description":"Journal of cancer research and clinical oncology, 135(2), pp.303-311; 2009","subitem_description_type":"Other"}]},"item_2_publisher_33":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Springer Verlag"}]},"item_2_relation_11":{"attribute_name":"PubMed番号","attribute_value_mlt":[{"subitem_relation_type":"isVersionOf","subitem_relation_type_id":{"subitem_relation_type_id_text":"18726116","subitem_relation_type_select":"PMID"}}]},"item_2_relation_12":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isVersionOf","subitem_relation_type_id":{"subitem_relation_type_id_text":"10.1007/s00432-008-0465-4","subitem_relation_type_select":"DOI"}}]},"item_2_rights_13":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"c Springer-Verlag 2008"},{"subitem_rights":"The original publication is available at www.springerlink.com"}]},"item_2_source_id_10":{"attribute_name":"書誌レコードID","attribute_value_mlt":[{"subitem_source_identifier":"AA0025708X","subitem_source_identifier_type":"NCID"}]},"item_2_source_id_7":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"01715216","subitem_source_identifier_type":"ISSN"}]},"item_2_source_id_8":{"attribute_name":"EISSN","attribute_value_mlt":[{"subitem_source_identifier":"1432-1335","subitem_source_identifier_type":"ISSN"}]},"item_2_version_type_16":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_ab4af688f83e57aa","subitem_version_type":"AM"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Kanda, Shigeru"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Kanetake, Hiroshi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Miyata, Yasuyoshi"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-12-23"}],"displaytype":"detail","filename":"JCRCO135_303.pdf","filesize":[{"value":"368.5 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"JCRCO135_303.pdf","url":"https://nagasaki-u.repo.nii.ac.jp/record/16360/files/JCRCO135_303.pdf"},"version_id":"238588b4-4ac8-4384-9b06-e76516ab818a"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"PI3-kinase","subitem_subject_scheme":"Other"},{"subitem_subject":"LY294002","subitem_subject_scheme":"Other"},{"subitem_subject":"Resistance","subitem_subject_scheme":"Other"},{"subitem_subject":"PTEN","subitem_subject_scheme":"Other"},{"subitem_subject":"ERK","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Loss of PTEN function may account for reduced proliferation pathway sensitivity to LY294002 in human prostate and bladder cancer cells.","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Loss of PTEN function may account for reduced proliferation pathway sensitivity to LY294002 in human prostate and bladder cancer cells."}]},"item_type_id":"2","owner":"2","path":["9"],"pubdate":{"attribute_name":"公開日","attribute_value":"2009-10-14"},"publish_date":"2009-10-14","publish_status":"0","recid":"16360","relation_version_is_last":true,"title":["Loss of PTEN function may account for reduced proliferation pathway sensitivity to LY294002 in human prostate and bladder cancer cells."],"weko_creator_id":"2","weko_shared_id":2},"updated":"2023-05-15T19:09:33.631153+00:00"}